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Abstract
Background: Rheumatoid Arthritis (RA) is a chronic autoimmune inflammatory disorder. Although the
pathogenesis of disease is unclear, it is well known that T cells play a major role in both development and
perpetuation of RA through activating macrophages and B cells. Since the lack of TNF-Related Apoptosis Inducing
Ligand (TRAIL) expression resulted in defective thymocyte apoptosis leading to an autoimmune disease, we
explored evidence for alterations in TRAIL/TRAIL receptor expression on peripheral T lymphocytes in the molecular
mechanism of RA development.
Methods: The expression of TRAIL/TRAIL receptors on T cells in 20 RA patients and 12 control individuals were
analyzed using flow cytometry. The correlation of TRAIL and its receptor expression profile was compared with
clinical RA parameters (RA activity scored as per DAS28) using Spearman Rho Analysis.
Results: While no change was detected in the ratio of CD4
+ to CD8
+ T cells between controls and RA patient
groups, upregulation of TRAIL and its receptors (both death and decoy) was detected on both CD4
+ and CD8
+ T
cells in RA patients compared to control individuals. Death Receptor-4 (DR4) and the decoy receptors DcR1 and
DcR2 on CD8
+ T cells, but not on CD4
+ T cells, were positively correlated with patients’ DAS scores.
Conclusions: Our data suggest that TRAIL/TRAIL receptor expression profiles on T cells might be important in
revelation of RA pathogenesis.
Background
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease, which affects the synovial membrane and even-
tually causes irreversible destruction of tendons,
cartilage, and bone [1-3]. It has long been suspected
that the inflammatory lesions result from an autoim-
mune response to joint-specific antigens primarily invol-
ving the cells of the immune system [4-7]. Although
disease commences with T cells recognizing antigen,
this recognition event also drives a chronic inflamma-
tory process involving the activation of macrophages
and B cells [8,9]. The chronic inflammation is in turn
perpetuated by activation of both CD4
+ and CD8
+
T cells [10].
Programmed cell death is an apoptotic mechanism by
which damaged cells are removed from the body.
Engagement of autoreactive T cells by self antigens
within the thymus induces deletion of potentially harm-
ful T cells. Defects in apoptosis lead to the persistence
of T cells recognizing self antigens which can induce
autoimmunity [11,12]. Clonally expanded T cells that
have served their functional purpose are also cleared
from the system through activation induced cell death
(AICD) involving cell surface FasL/Fas receptor interac-
tion [13]. Children with defective Fas-mediated T lym-
phocyte apoptosis exhibit a disorder known as
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FasL, TNF has also been involved in AICD [16],
although unlike CD95, TNF initiates and exacerbates
autoimmune diseases. A third member of TNF super-
family is the TNF Related Apoptosis Inducing Ligand
(TRAIL) [17]. In the immune system, TRAIL is
expressed on the surface of activated T lymphocytes.
Five different receptors interact with TRAIL: TRAIL
Receptor-1 (TRAIL-R1/also referred to as DR4), TRAIL
Receptor-2 (TRAIL-R2/DR5), TRAIL Receptor-3
(TRAIL-R3/DcR1), TRAIL Receptor-4 (TRAIL-R4/
DcR2), and osteoprotegrin (OPG) [18,19]. DR4 and DR5
are the genuine death receptors inducing apoptosis
whereas DcR1 and DcR2 function as decoy receptors
and physiologically block apoptosis [20,21], which might
thus contribute to the pathogenesis of autoimmunity
[22,23]. Like CD95L, TRAIL has been reported to be a
potent inhibitor of autoimmune arthritis [24]. Unlike
TNF and FasL, TRAIL inhibits the activation and prolif-
eration of lymphocytes in vivo, but does not delete them
from the system.
It is apparent then that FasL, TNF and the TRAIL/
TRAIL receptor system are involved in T cell activation
and/or deletion [25]. Accordingly, here we demonstrate the
potential usage of TRAIL and the expression profile of its
receptors on peripheral T cell subsets as markers to moni-
tor the prognosis of patients with rheumatoid arthritis.
Methods
Clinical Assessment of Patients with Rheumatoid Arthritis
20 RA patients and 12 age-/sex-matched control indivi-
duals were enrolled in the study conducted at the Rheu-
matology Clinic of Akdeniz University Hospitals. RA
patients were classified according to the American
Rheumatism Association 1987 revised criteria. DAS28-3
scoring (including tender joint counts, swollen joint
counts and erythrocyte sedimentation rate-ESR) was
used for each RA patient to assess the severity of dis-
ease. RA patients previously not treated with disease
modifying anti-rheumatic drugs (anti-TNF agents) were
admitted to the study. These patients had the history of
receiving either non-steroidal anti-inflammatory drugs
(NSAIDs) or analgesics prior to analysis.
Collection and analysis of blood samples
Analysis of peripheral blood lymphocytes was performed
by direct immunofluorescence flow cytometry using a
Coulter EPICS ALTRA XL instrument. The following
monoclonal antibodies (mAb) were used: Phycoerythrin
(PE) anti-human DR4 (CD261, TRAIL-R1, Cat No: 12-
6644-73, eBioscience Inc., San Diego, CA, USA), PE anti-
human DR5 (CD262, TRAIL-R2, Cat No: 12-9908-73,
eBioscience Inc., San Diego, CA, USA), PE anti-human
DcR1 (CD263, TRAIL-R3, TRAILR3, LIT, TRID Cat
No: 12-6238-73, eBioscience Inc., San Diego, CA, USA),
PE anti-human DcR2 (CD264, TRAIL-R4, TRAILR4,
TRUNDD, TNFRSF10 D Cat No: 12-6239-73,
eBioscience Inc., San Diego, CA, USA), PE anti-human
TRAIL (CD253 Cat No: 12-9927-73, eBioscience Inc.,
San Diego, CA, USA), Fluorescein isothiocyanate (FITC)
anti-human CD4 (L3T4 Cat No: A07750, Beckman Coul-
ter, Immunotech, Marseille, France), FITC anti-human
CD8 (Cat No: IM0451U, Beckman Coulter, Immunotech,
Marseille, France), PE Mouse IgG1 ( Isotype Control
Cat No: 12-4714-73, eBioscience Inc., San Diego, CA,
USA), FITC Mouse IgG1 ( Isotype Control Cat No:
A07795, Beckman Coulter, Immunotech, Marseille,
France) and FITC Mouse IgG2a (Isotype Control Cat No:
11-4724-73, eBioscience Inc., San Diego, CA, USA).
Flow Cytometry Procedure
Reaction conditions for FC were as follows: 50 μlo f
each sample was diluted with 50 μl PBS solution (phos-
phate buffered saline; 0.01 M sodium phosphate, 0.145
M sodium chloride, Ph 7.2), and stained using 10 μlo f
either FITC (Fluorescein isothiocyanate) conjugated
mouse monoclonal antihuman CD4 antibody or FITC
conjugated mouse monoclonal antihuman CD8 anti-
body. PE (Phycoerythrin) conjugated mouse monoclonal
antihuman TRAIL or its receptor antibodies were added
subsequently to each tube. Both the activation status of
T cells (CD4
+CD25
+)a n dt h ea m o u n to fr e g u l a t o r yT
cells (CD4
+CD25
+FoxP3
+) present were revealed using
CD25 ECD (Beckman Coulter, 6607112) and APC-anti-
human Foxp3 (eBioscience, 17-4776-73) antibodies.
Tubes were incubated in the dark at room temperature
for 20 minutes. Erythrocytes were eliminated from PBL
using ammonium chloride lysing solution. After two
Figure 1 Scatter dot plots of peripheral blood samples from 12
healthy control individuals and 20 RA patients showing the
ratio of T cell subsets (CD4
+ and CD8
+) by flow cytometry.
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Page 2 of 9Figure 2 TRAIL and its receptor (both death and decoy) expression profile on CD4
+ Tc e l l s . A scattered dot plot profile of TRAIL and its
receptors is provided in Panel A. Solid circles indicate RA patients while dots represent control individuals. Error bars display mean (±) SEM.
Representative flow cytometric analyses of a control individual (upper panels) and an RA patient (lower panels) are shown in Panel B, while
Panel C shows the relative increase in TRAIL and its receptors on CD4
+ T cells of RA patients compared to controls.
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Page 3 of 9washes with PBS, the cells were resuspended and ana-
lyzed by flow cytometry. A calibration based on lympho-
cyte gating was performed on EPICS Altra XL system
using CD45 fluorescence and side scatter parameters
prior to analysis. The peripheral blood samples were
analyzed within 6 hours so that the gate could still be
drawn around lymphocytes. Isotype matched antibodies
were included to control for non-specific binding. All
results were analyzed using Expo32 Altra software
(Beckman-Coulter, Fullerton, CA).
Ethics
Written informed consent relating to the Declaration of
H e l s i n k iw a so b t a i n e df r o ma l lp a t i e n t s .T h es t u d yw a s
approved by Akdeniz University Local Committee on
Ethics.
Statistical Analysis
The statistical package for the Social Sciences 13.0 soft-
ware for Windows (SPSS Inc., Chicago, Ill) and Graph-
Pad Prism version 5 (La Jolla, CA, USA) were used to
plot the data and perform statistical analyses. In addi-
tion, SmartDraw Health Science Edition (San Diego,
CA, USA) was used as a graphics software package.
Normality tests were conducted using a Shapiro-Wilk
method. T cell subsets (CD4
+ and CD8
+ T cells) in both
groups displayed a normal distribution. Thus, a non-
parametric unpaired student’s T test was used to evalu-
ate CD4
+/CD8
+ T cell ratios. On the other hand, a
Gaussian distribution was not observed between normal
versus RA patients when analyzing TRAIL and TRAIL
receptor expression profiles. For this reason, Mann-
Whitney U test was used to compare CD4
+ versus
CD8
+ T cell associated TRAIL marker expression in
patients. All correlation analyses used Spearman’sR h o
tests.
Results
Flow Cytometric Analysis of Peripheral Blood
T Lymphocytes
Given the heterogeneous nature of rheumatoid arthritis,
and evidence for variation in the ratio of CD4
+/CD8
+ T
cells changes in autoimmune diseases such as Systemic
Lupus Erythematosus (SLE) [26-28], we first character-
ized the composition of peripheral blood T cell subsets
in RA patients using flow cytometry. Nonparametric
unpaired student’s T test was used to detect possible
differences in the two T cell subsets between normal
versus RA patients. As shown in Figure 1, no difference
was detected in the ratio of CD4
+ (p = 0.63) to CD8
+
(p = 0.22) T cells between the two groups. We conclude
that, unlike Systemic Lupus Erythematosus, disease sta-
tus does not alter the ratio of CD4
+ to CD8
+ T cell sub-
sets in RA.
Membrane bound TRAIL and its receptor expression
profile on peripheral CD4
+ T lymphocytes in RA patients
versus control individuals
During the development of RA, CD4
+ T cells initiate
and regulate several cell-mediated immune processes
that cause synovial inflammation and joint destruction
in response to activation by antigen presentation. We
next examined the CD4
+ T lymphocyte associated cell-
surface expression profile of TRAIL and its receptors
Table 1 Spearman rho correlation analysis of TRAIL and its receptors present on CD4
+ T cells isolated from RA
patients
RA-CD4 Spearman’s Rho DR4 DR5 DcR1 DcR2 TRAIL
DR4 correlation Coefficient 1.000 .620(**) .116 .255 .764(**)
Sig. (2-tailed) . .004 .626 .277 .000
N 2 02 02 02 02 0
DR5 correlation Coefficient .620(**) 1.000 .470(**) .416 .374
Sig. (2-tailed) .004 . .037 .068 .104
N 2 02 02 02 02 0
DcR1 correlation Coefficient .116 .470(**) 1.000 .639(**) .086
Sig. (2-tailed) .626 .037 . .002 .718
N 2 02 02 02 02 0
DcR2 correlation Coefficient .255 .416 .639(**) 1.000 .414
Sig. (2-tailed) .277 .068 .002 . .070
N 2 02 02 02 02 0
TRAIL correlation Coefficient .764(**) .374 .086 .414 1.000
Sig. (2-tailed) .000 .104 .718 .070 .
N 2 02 02 02 02 0
** Correlation is significant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).
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Page 4 of 9Figure 3 Panel A: CD8
+ T cell associated TRAIL and its receptor expression profile. TRAIL and its receptor expression profile of CD8
+ T cells
gathered from 20 RA patients and 12 healthy controls are shown as a scatter dot plot. Error bars represent mean (±) SEM. Panel B shows
representative FC for TRAIL and its receptor expression on CD8
+ T cells (upper panels show healthy control, lower panels are obtained from an
RA patient). Panel C shows the relative increase in TRAIL and its receptors on CD8
+ T cells on RA cells (vs control).
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Page 5 of 9isolated from either healthy volunteers or RA patients
using flow cytometry. The Mann-Whitney U test was
used to compare the two groups. As shown in Figure
2A, CD4
+ T cells obtained from RA patients exhibited
higher levels of expression of TRAIL and its death/
decoy receptors compared to cells from control indivi-
duals (p < 0.05). Representative flow cytometric analyses
of CD4
+ T cells isolated from a healthy individual and
an RA patient are shown in Figure 2B, while Figure 2C
indicates the relative increase in marker expression
levels. These data show a 35-fold increase in DcR1
expression with a 10-15-fold increase in the other
markers.
Using a Spearman Rho correlation test to evaluate
correlations between expression of TRAIL and TRAIL
receptors on CD4
+ T cells in RA patients, we found
increased DR4 expression was correlated with an
increase in both DR5 and TRAIL (Table 1). In addition,
D c R 1a n dD c R 2e x p r e s s i o ns h o w e ds t r o n gc o r r e l a t i o n
(p < 0.01).
CD8
+ T cell associated TRAIL and its receptor expression
profile in RA
We next investigated the expression of TRAIL and its
receptors on CD8
+ T cells of RA patients and compared
with healthy controls, similar to CD4
+ T cells, we found
significant differences between the two groups as shown
in Figure 3A (p < 0.05). Representative FC data from a
patient and control are shown in Figure 3B, with Figure
3C indicating the relative increase in CD8
+ T cell asso-
ciated TRAIL and its receptor expression. In this case
increased DcR1 expression (about 66 fold) was the most
marked. A correlation between CD8
+ T cell associated
TRAIL and receptor expression was investigated using
Spearmen Rho Correlation analysis. As shown in Table
2, a correlation among the death and the decoy recep-
tors as well as with TRAIL death ligand expression was
observed.
A non-parametric Mann-Whitney U test was adminis-
tered to investigate statistical differences in expression
levels between CD4
+ and CD8
+ T cell associated TRAIL
and its receptors in patients with RA. Our results indi-
cated that expression levels of TRAIL and its receptors
were higher on CD8
+ T cells (Figure 3A) than on CD4
+
T cells (Figure 2A).
CD8
+ T cell associated DR4, DcR1 and DcR2 expression
levels correlated with DAS28 scores in RA patients
F i n a l l yw ei n v e s t i g a t e de v i d e n c ef o rac o r r e l a t i o n
between TRAIL and its receptor expression profile and
the severity of disease in RA patients. Interestingly only
CD8
+ T cell associated (Figure 4) but not CD4
+ Tc e l l
associated (data not shown) DR4, DcR1 and DcR2
expression levels correlated with DAS28 scores in RA
patients.
T cell activation status of newly diagnosed RA patients
CD25 is one commonly used marker for recently acti-
vated T cells [29]. In order to document the activation
status of T cells in RA patients; another set of flow cyto-
metry assay was conducted. As shown in Table 3, the
percentage of CD4
+CD25
+ T cells was statistically higher
in RA patients compared to control individuals. However,
as shown before both activated and regulatory T cells
(Treg) can express CD25 marker on the cell surface [30].
To distinguish these two, FoxP3 staining was employed
Table 2 Spearman rho correlation analysis of CD8
+ T cell associated TRAIL and its receptors obtained from RA patients
RA-CD8 Spearman’s Rho DR4 DR5 DcR1 DcR2 TRAIL
DR4 correlation Coefficient 1.000 .868(**) .948(**) .740(**) .744(**)
Sig. (2-tailed) . .004 .000 .000 .000
N 2 02 02 02 02 0
DR5 correlation Coefficient .868(**) 1.000 .784(**) .738(**) .632(**)
Sig. (2-tailed) .000 . .000 .000 .003
N 2 02 02 02 02 0
DcR1 correlation Coefficient .948(**) .784(**) 1.000 .773(**) .689(**)
Sig. (2-tailed) .000 .000 . .000 .001
N 2 02 02 02 02 0
DcR2 correlation Coefficient .740(**) .738(**) .773(**) 1.000 .525(*)
Sig. (2-tailed) .000 .000 .000 . .017
N 2 02 02 02 02 0
TRAIL correlation Coefficient .744(**) .632(**) .689(**) .525(*) 1.000
Sig. (2-tailed) .000 .003 .001 .017 .
N 2 02 02 02 02 0
** Correlation is significant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).
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Page 6 of 9as described in Materials and Methods. No difference
was noted in the amount of Treg (CD4
+CD25
+ FoxP3
+)
between RA and control patients (Table 3).
Discussion
It has previously been reported that negative selection of
T cells in the thymus is controlled by TRAIL [25]. For
example, mice deficient in TRAIL had a severe defect in
thymic deletion of T cells and were hypersensitive to col-
lagen-induced arthritis [31]. Evidence for functional conse-
quences of TRAIL over-expression in autoimmune
diseases including rheumatoid arthritis has emerged from
gene therapy studies [32]. Although TRAIL is not cyto-
toxic to normal cells [33], hyperplastic human RA synovial
fibroblasts in culture and RA-activated rabbit synovial tis-
sue in vivo were sensitive to adenoviral delivery of human
TRAIL [34]. The effect of TRAIL expression on blood
lymphocytes was reported to be different (killing versus
suppression) than that observed with RA synovial cells.
These studies suggested that TRAIL can inhibit the activa-
tion and proliferation of lymphocytes in vivo, but does not
necessarily delete them from the system [35].
The TRAIL/TRAIL receptor system has recently been
implicated as a disease activation marker in cancer.
High DcR2 expression levels in patients with prostate
cancer (PCa) indicate a poorer prognosis, with this mar-
ker strongly correlated with high Gleason Scores, Pros-
tate Specific Antigen (PSA) recurrence and decreased
survival in PCa patients [36]. In patients with invasive
ductal carcinoma, however, high levels of DR4 expres-
sion are positively correlated with tumor grade and with
poor prognosis [37]. Two recent studies have linked
high levels of endogenous TRAIL expression to
increased cell death in human pancreatic tissue, sup-
porting the idea that TRAIL might be implicated in the
development of autoimmune diseases such as Type 1
Diabetes [38,39]. Despite this information, there is no
information concerning the profile of the TRAIL/TRAIL
receptor system in the development of RA.
We analyzed peripheral blood lymphocytes of 20 RA
patients and 12 control individuals by flow cytometry to
detect their TRAIL/TRAIL receptor profile. T cell lym-
phocytes of healthy control individuals expressed low
levels of TRAIL and TRAIL receptors on the cell sur-
face. While this is in accordance with a study conducted
by Lu et al. [40], Hasegawa et al. have shown that only
DcR2 expression but no other TRAIL receptor expres-
sion was detectable on CD8+ T cells [41]. Differences
between these studies including ours could be attributed
to differences in monoclonal antibodies used. Neverthe-
less, both CD4
+ and CD8
+ T lymphocytes of RA
patients displayed higher levels of TRAIL and its recep-
tors on the cell surface compared to healthy control
Figure 4 Correlation between DR4
+ (Panel A), DcR1
+ (Panel B)
and DcR2
+ (Panel C) expression levels and RA disease activity
(DAS28 Score)-Spearman Rho correlation analysis.
Table 3 T cell activation marker profile and Treg status in
RA versus healthy control patients
Cell Subsets RA
(% cell ± SD)
Control
(% cell ± SD)
p value
CD4
+ CD25
+ 4,9 ± 2,9 3,1 ± 2,0 0,001
CD4
+ CD25
+ FoxP3
+ 0,8 ± 1,9 0,6 ± 0,4 0,259
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patients with benign prostate hyperplasia by the amount
of TRAIL/TRAIL receptor present in prostate tissue
[42] our observations suggest that it might be useful to
monitor TRAIL/TRAIL receptor expression in periph-
eral blood lymphocytes in RA patients at diagnosis and
during the course of their disease. The most dramatic
change in the amount of TRAIL/TRAIL receptor pre-
sent on peripheral blood lymphocytes of RA patients
was the increased DcR1 expression seen in both CD4
+
and CD8
+ T cells. Recently, elevated expression of DcR1
was detected in antigen specific T cells of patients with
multiple sclerosis (MS) [22]. These antigen specific T
cell clones were also resistant to TRAIL mediated apop-
tosis. One interpretation of these data is that antigen
specific T cell clones increase their survival following
DcR1 upregulation.
Based on our flow cytometry analysis, RA patients dis-
played higher levels of activated T cells compared to
healthy controls. This finding is in accordance with pre-
vious studies demonstrating the presence of higher levels
of CD4
+CD25
+ peripheral blood lymphocytes in RA
patients compared to healthy individuals [43,44]. How-
ever we did not observe any change in the level of CD4
+CD25
+ FoxP3
+ T cells between RA and control groups.
In accordance with previous studies, no relationship was
found between disease activity and CD4
+CD25
+ or CD4
+CD25
+ FoxP3
+ T cells in RA patients [45]. Whether any
subtle increase in TRAIL or TRAIL receptor expression
observed on CD4+ T cells in RA patients is simply a con-
sequence of T cell activation remains to be clarified.
Conclusions
Clinical evaluation of RA patients involves RA activity
scoring (DAS28). Intriguingly, only the CD8
+ Tc e l l
associated DR4, DcR1 and DcR2 expression levels corre-
lated with DAS28 scores in patients with RA, implying
that altered TRAIL receptor profiles on CD8
+ Tc e l l
subsets rather than on CD4
+ T cells is more important
in terms of disease severity.
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